Lectures and seminars What is life? P4 medicine and the future health care

31-03-2021 3:00 pm Add to iCal
Online Zoom meeting. See details below

Speaker: Lee Hood, Institute of Systems Biology (ISB), Seattle
Host: Ingemar Ernberg

Zoom information


Meeting ID: 639 4932 9836

Passcode: 105194    


Leroy "Lee" Edward Hood established the first cross-disciplinary biology department, the Department of Molecular Biotechnology (MBT), at the University of Washington in 1992, and co-founded the Institute for Systems Biology in 2000. Hood is credited with introducing the term "systems biology",and advocates for "P4 medicine", medicine that is "predictive, personalized, preventive, and participatory. Scientific American counted him among the 10 most influential people in the field of biotechnology in 2015.

Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. His  protein sequencer, DNA synthesizer, peptide synthesizer, and DNA sequencer were commercialized through Applied Biosystems, Inc. and the ink-jet technology was commercialized through Agilent Technologies. The automated DNA sequencer was an enabling technology for the Human Genome Project. The peptide synthesizer was used in the synthesis of the HIV protease by Stephen Kent and others, and the development of a protease inhibitor for AIDS treatment.


21st century medicine is undergoing a revolution that argues healthcare should be predictive, preventive, personalized and participatory (P4) and acknowledges it has two major domains—wellness and disease.  The effective implementation of P4 healthcare arises from the idea that the complexity of human biology and the complexity  of disease can only be assessed in each individual with genomic and deep phenotypic analyses (e.g., blood analytes, gut microbiome, digital health measurements, etc).  Thus 21st century medicine is about following longitudinally the health trajectory of each individual and optimizing wellness and detecting and avoiding transitions to disease.  I will report on the analyses of longitudinal deep phenotyping data from about 5000 well individuals from Arivale—a company bringing quantitative or scientific wellness to consumers that closed down about 9 months ago.  I will also talk about a new proposal that we are just initiating to implement genomic and deep phenotyping analyses on 1-million  patients (the million person project) at Providence St. Joseph Health (PSJH), the 3rd largest healthcare non-profit institute over a 5 year period—this project will be the catalyst for achieving 21st century medicine and will bring this new approach to approximately 10% of the  PSJH patients. It offers unique possibilities for improving clinical service, the possibility to discover thousands of new actionable possibilities, each  of which can improve health,  from the integration of genomic and phenomic data, the possibility of creating a myriad of new companies (e.g., new data generation assays, AI for managing for  physicians the  thousands of actionable possibilities, novel computational platforms for integration and analyses, etc.).  It will be the ultimate manifestation of scientific (or quantitative) wellness.  It turns out that 21st century medicine will give us powerful new approaches to solving contemporary medicine’s four largest challenges:  improving quality of health care, reducing its costs, leading us to age in a healthy manner (to deal with the large aging population), and provide us with an approach to ending most chronic disease by early prediction  and prevention.  I will discuss all of these issues and more.